Results 181 to 190 of about 24,063,572 (372)
Alectinib resistance in ALK+ NSCLC depends on treatment sequence and EML4‐ALK variants. Variant 1 exhibited off‐target resistance after first‐line treatment, while variant 3 and later lines favored on‐target mutations. Early resistance involved off‐target alterations, like MET and NF2, while on‐target mutations emerged with prolonged therapy.
Jie Hu+11 more
wiley +1 more source
Background: Medicaid is a means-tested health insurance program for low-income adults (∼30%), children (∼40%), individuals with disabilities (15%) and some elderly patients that are dual Medicare and Medicaid eligible (15%).
Patrick Saunders, MD+6 more
doaj
Modified radical mastectomy for level III axillary lymph node clearance: a case report. [PDF]
Zhang M, Yang L, Hou L, Wang Z, Zhang J.
europepmc +1 more source
This study used longitudinal transcriptomics and gene‐pattern classification to uncover patient‐specific mechanisms of chemotherapy resistance in breast cancer. Findings reveal preexisting drug‐tolerant states in primary tumors and diverse gene rewiring patterns across patients, converging on a few dysregulated functional modules. Despite receiving the
Maya Dadiani+14 more
wiley +1 more source
Demand for regional level III neonatal services is not reduced during national COVID lockdowns. [PDF]
Kenney I+7 more
europepmc +1 more source
B‐cell chronic lymphocytic leukemia (B‐CLL) and monoclonal B‐cell lymphocytosis (MBL) show altered proteomes and phosphoproteomes, analyzed using mass spectrometry, protein microarrays, and western blotting. Identifying 2970 proteins and 316 phosphoproteins, including 55 novel phosphopeptides, we reveal BCR and NF‐kβ/STAT3 signaling in disease ...
Paula Díez+17 more
wiley +1 more source
Changes in cardinal ligament length and curvature with parity and prolapse and their relation to level III hiatus measures. [PDF]
Cheng W+4 more
europepmc +1 more source
Nuclear prothymosin α inhibits epithelial‐mesenchymal transition (EMT) in lung cancer by increasing Smad7 acetylation and competing with Smad2 for binding to SNAI1, TWIST1, and ZEB1 promoters. In early‐stage cancer, ProT suppresses TGF‐β‐induced EMT, while its loss in the nucleus in late‐stage cancer leads to enhanced EMT and poor prognosis.
Liyun Chen+12 more
wiley +1 more source